News
7d
MedPage Today on MSNIsturisa's New Indication; Wegovy Pill Submitted to FDA; Type 5 Diabetes?Orforglipron, a daily GLP-1 receptor agonist pill, lowered HbA1c by up to 1.6% and body weight by 7.9% in a phase III trial ...
Bad news for Pfizer (NYSE: PFE) turned into good news for Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Viking Therapeutics (NASDAQ: VKTX) Monday morning, each of which is rising on Pfizer ...
We recently published a list of Jim Cramer Reacts to the Surprise Market Surge and Highlights 8 Key Stocks In this article, we are going to take a look at where Eli Lilly and Company (NYSE ...
Eli Lilly LLY underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table encapsulates their recent ratings, offering a ...
ATLANTA, April 11, 2025 /PRNewswire/ -- On April 01, 2025, OrderlyMeds received a Cease-and-Desist letter from Eli Lilly regarding the compounding of Tirzepatide. This is our open response.
A stock is considered to be oversold if the RSI reading falls below 30. In trading on Thursday, shares of Eli Lilly (Symbol: LLY) entered into oversold territory, hitting an RSI reading of 29.5 ...
Shares of AstraZeneca (AZN), Pfizer (PFE), Eli Lilly (LLY), Novo Nordisk (NVO), Johnson & Johnson (JNJ), GSK (GSK), and Sanofi (SNY) all declined. Gold futures climbed and the yield on the 10-year ...
In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares closed yesterday at $726.24.
After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock is, again, testing multiyear lows. The $700 billion pharmaceutical giant ...
One of them is the pharmaceutical industry. However, some major executives in the sector are not optimistic, including Eli Lilly's (NYSE: LLY) CEO, David Ricks. Start Your Mornings Smarter!
Following a three-day selloff amid market turmoil attributed to the Trump administration’s sweeping tariffs announced last week, Eli Lilly (NYSE:LLY) shares traded higher in the premarket on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results